The Veilguard's failure on a lack of a shared world, that raises questions about what EA will demand from Mass Effect 5.

Now that Dragon Age: The Veilguard has shipped and BioWare is free to pour its resources into the fifth entry in the Mass Effect series, players are naturally getting excited. But according to ...

BioWare is focusing on Mass Effect 4 now that Dragon Age: The Veilguard is out. The next Mass Effect game is likely not far along enough to support the entire team's involvement.

Natasha Landell-Mills, head of stewardship at Sarasin & Partners, a UK asset manager, said: “The chilling effect from the increasing politicisation of climate change in the US is certainly ...

“We reserve the right to resume the war if necessary, with American support.” Netanyahu's statement came a day before a ceasefire is set to take effect. "We are thinking of all our hostages ...

Copyright 2025 The Associated Press. All Rights Reserved. The U.N. chief has expressed the support of the international community to Lebanon for a speedy recovery ...

The agreement follows months of intermittent negotiations mediated by Egypt and Qatar, with support from the United States, and bring end to war that has disrupted the ... About 90% of Gaza’s 2.3 ...

For the first time since Independence, an Indian Prime Minister has commissioned three frontline ships into the Navy. Prime Minister Narendra Modi unveiled the guided missile destroyer INS Surat, ...

Mass Effect's producer has suggested players should replay the second game's DLC, leading to fresh speculation about the upcoming Mass Effect 4.

“One of the best and most beautiful parts of the United States of America is burning down to the ground. It’s ashes, and Gavin Newscum should resign,” Trump posted on Truth Social. “This i ...

The European Union has transferred €3 billion to Ukraine’s state budget, marking the first disbursement from frozen Russian assets under the G7’s Extraordinary ... s lips and everyone’s headlines. War ...

Today, a brief rundown of news involving Pfizer, AbbVie and Royalty Pharma, as well as updates from Biogen and Alkeus Pharmaceuticals that you may have missed. Barinthus Biotherapeutics on Friday said ...